Management of Molecular-Targeted Therapy for Chronic Myelogenous Leukemia-Reference-Cited by-同舟云学术

Management of Molecular-Targeted Therapy for Chronic Myelogenous Leukemia

Published:2003-07 Issue:7 Volume:15 Page:292-296
ISSN:1041-2972
Container-title:Journal of the American Academy of Nurse Practitioners
language:en
Short-container-title:J Amer Acad Nurse Practitioners

Author:

Ault Patricia,Kaled Suzan,Rios Mary Beth

Publisher

Wiley

Subject

General Nursing

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1745-7599.2003.tb01310.x/fullpdf

Reference30 articles.

1. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.

2. J. E. Cortes, M. Talpaz, R. Giles, M. B. Rios, and D. Thomas (2002 ). High-dose imatinib mesylate (ST1571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alfa (IFN) .Proceedings of ASCO, Abstract no. 1044.

3. Chronic myelogenous leukemia: A review

4. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

5. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Side Effects Associated With Intolerance to BCR-ABL Inhibitors in Patients With Chronic Myeloid Leukemia;Clinical Journal of Oncology Nursing;2011-11-26

2. Treatment of Chronic Myeloid Leukemia Following Imatinib Resistance;Clinical Journal of Oncology Nursing;2009-01-01

3. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia;Journal of Oncology Pharmacy Practice;2008-08-27

4. Innovations in Antineoplastic Therapy;Nursing Clinics of North America;2005-03